Oklacytynib w dermatologii weterynaryjnej
Piśmiennictwo
Carrasco I, Ferrer L, Puigdemont A.: Efficacy of oclacitinib for the control of feline atopic skin syndrome: correlating plasma concentrations with clinical response. „J Fel Med Surg”, 2021.
Carrasco I., Martınez M., Albinyana G.: Beneficial effect of oclacitinib in a case of feline pemphigus foliaceus. „Vet Dermatol”, 2021, 32, 299-301.
Collard W.T., Hummel B.D., Fielder A.F., King V.L., Boucher J.F., Mullins M.A., Malpas P.B., Stegemann M.R.: The pharmacokinetics of oclacitinib maleate, a Janus kinase inhibitor, in the dog. „J Vet Pharmacol Therap”, 2014, 37, 279-285.
Colombo S., Cornegliani L., Vercelli A., Fondati A.: Ear tip ulcerative dermatitis treated with oclacitinib in 25 dogs: a retrospective case series. „Vet Dermatol”, 2021, 32, 363-e100.
Cosgrove S., Wren J., King V., Wheeler D., Stegemann M.: Multicentre clinical trial to evaluate theefficacy and field safety of oclacitinib. „Vet Dermtol”, 2012, 23 (s1), 38.
Cosgrove S.B, Cleaver D.M, King V.L, Gilmer A.R, Daniels A.E., Wren J.A., Stegemann M.R.: Long-term compassionate use of oclacitinib in dogs with atopic and allergic skin disease: safety, efficacy and quality of life. „Vet Dermatol”, 2015, 26: 171-e35.
Cosgrove S.B., Wren J.A., Cleaver D.M., Martin D.D., Walsh K.F., Harfst J.A., Follis S.L., King V.L., Boucher J.F., Stegemann M.R.: Efficacy and safety of oclacitinib for the control of pruritus and associated skin lesions in dogs with canine allergic dermatitis. „Vet Dermatol”, 2013, 24, 479-e114.
Cosgrove S.B., Wren J.A., Cleaver D.M., Walsh K.F., Follis S.L., King V.L., Tena J.S., Stegemann M.R.: A blinded, randomized, placebo-controlled trial of the efficacy and safety of the Janus kinase inhibitor oclacitinib (ApoquelR) in client-owned dogs with atopic dermatitis. „Vet Dermatol”, 2013, 24, 587-597, e141-2.
Denti D., Caldin M., Ventura L., De Lucia M.: Prolonged twice-daily administration of oclacitinib for the control of canine atopic dermatitis: ...
którzy są subskrybentami naszego portalu.
i ciesz się dostępem do bazy merytorycznej wiedzy!